For example, imatinib reduces the severity of pulmonary hypertension and improves survival in MCT rats 250; in PAH patients it increases 6MWD and reduces PVR, but it is associated with an increased ...

At present, PROTACs have garnered significant attention as a burgeoning therapeutic approach. Relying on endogenous E3 ubiquitin ligases, PROTACs achieve the catalytic degradation of target proteins ...

Inhibition of Bcr-Abl kinase activity by imatinib for the treatment of chronic myeloid leukemia (CML) currently serves as the paradigm for targeting dominant oncogenes with small molecules. We ...

Imatinib provides a second example of serendipitious target discovery. ... The broad kinome profiling of clinically approved and investigational kinase inhibitors is likely to help identify such ...

BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered clinical-stage biopharma company, today announced that the company will present groundbreaking research across ...

Conclusions: The 10-year follow-up analysis of the binimetinib plus imatinib combination phase II study demonstrated robust and sustained clinical benefit in PFS, OS and DSS for patients with ...

Together, ziftomenib plus imatinib may enhance KIT recycling while reducing KIT transcription. This combination is currently being investigated clinically in patients with imatinib-sensitive and ...